P 53

Drug Profile

P 53

Alternative Names: P53

Latest Information Update: 24 Apr 2007

Price : $50

At a glance

  • Originator Phytopharm
  • Class Antipruritics; Antipsoriatics
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Pruritus; Psoriasis

Most Recent Events

  • 01 Feb 2000 No-Development-Reported for Psoriasis in United Kingdom (Topical)
  • 10 Dec 1998 Phase-II clinical trials for Pruritus in United Kingdom (Topical)
  • 12 Feb 1998 Phase-II clinical trials for Psoriasis in United Kingdom (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top